NCT07655648Completed
Dual-tracer PET Radiomics for Prostate Cancer Stratification
Dual-tracer PET/CT Interpretable Radiomics for Pathological Classification and Prognostic Stratification of Prostate Cancer
Source: ClinicalTrials.gov · Last updated 18 Jun 2026
Brief summary (registry, in English)
This single-center retrospective study aims to develop an interpretable radiomics model based on dual-tracer PET/CT to preoperatively predict the postoperative pathological Gleason grade group in treatment-naïve prostate cancer patients. A machine learning-based three-class prediction model will be constructed and interpreted using SHAP. Its performance will be compared with systematic biopsy results, assessing grading accuracy and prognostic value for biochemical recurrence-free survival.
- Status (registry)
- Completed
- Study type
- Observational
- Enrollment
- 100 (actual)
- First submitted
- 12 Jun 2026
- Start date
- 1 Jan 2020
- Primary completion date
- 1 May 2026
- Lead sponsor
- Xiangya Hospital of Central South University
- Diseases
- Prostate cancer, Childhood cancers
- NCT number
- NCT07655648
What you commit to
- Study type: Observational
- Participants enrolled: 100
- From 1 Jan 2020 to the primary completion date, 1 May 2026
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Other illness
- PET/CT performed after any prostate cancer-related treatment
Other
- Unavailability of imaging or pathological data
- Interval between PET and biopsy \> 3 months
- Interval between biopsy and RP \> 1 month
Who the study is looking for
- Treatment-naïve prostate cancer with subsequent radical prostatectomy (RP)
- Availability of presurgical dual-tracer PET/CT images, biopsy, and RP pathology data
Sex: Male · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Department of Nuclear Medicine, Xiangya Hospital, Central South University Coordinator of this site? Confirm its status | Changsha | China | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.